KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Return on Capital Employed (2021 - 2023)

AbCellera Biologics (ABCL) has disclosed Return on Capital Employed for 3 consecutive years, with 0.17% as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Return on Capital Employed fell 32.0% year-over-year to 0.17%, compared with a TTM value of 0.17% through Dec 2023, down 32.0%, and an annual FY2024 reading of 0.23%, down 6.0% over the prior year.
  • Return on Capital Employed was 0.17% for Q4 2023 at AbCellera Biologics, down from 0.05% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.32% in Q1 2021 and bottomed at 0.17% in Q4 2023.
  • Average Return on Capital Employed over 3 years is 0.16%, with a median of 0.21% recorded in 2022.
  • The sharpest move saw Return on Capital Employed dropped -3bps in 2022, then crashed -32bps in 2023.
  • Year by year, Return on Capital Employed stood at 0.18% in 2021, then dropped by -17bps to 0.15% in 2022, then plummeted by -213bps to 0.17% in 2023.
  • Business Quant data shows Return on Capital Employed for ABCL at 0.17% in Q4 2023, 0.05% in Q1 2023, and 0.15% in Q4 2022.